DBTX

Decibel Therapeutics Stock Price

7.96
-0.31 (-3.75%)
Upgrade to Real-Time
Afterhours (Closed)
7.96

Low
6.18

52 Week Range

High
24.35

Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
$30.66
Canadian Level 1 + USA
Monthly Subscription
for only
$38.05
Small Cap Basic
Monthly Subscription
for only
$33.03
VAT not included
Company Name Stock Ticker Symbol Market Type
Decibel Therapeutics Inc DBTX NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.31 -3.75% 7.96 20:00:00
Open Price Low Price High Price Close Price Prev Close
8.13 7.73 8.85 7.96 8.27
Bid Price Ask Price Spread News
7.75 9.40 1.65 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,338 134,846 $ 8.10 $ 1,091,601 97,773 6.18 - 24.35
Last Trade Time Type Quantity Stock Price Currency
16:01:19 formt 400 $ 7.96 USD

Decibel Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 198.22M 24.90M 15.58M $ - $ - -1.53 -13.00
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - -12.20M 0.30%

more financials information »

Decibel Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical DBTX Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week8.809.387.738.5497,456-0.84-9.55%
1 Month8.619.517.568.4797,817-0.65-7.55%
3 Months12.1912.886.189.0489,817-4.23-34.7%
6 Months21.2024.356.1813.41148,398-13.24-62.45%
1 Year21.2024.356.1813.41148,398-13.24-62.45%
3 Years21.2024.356.1813.41148,398-13.24-62.45%
5 Years21.2024.356.1813.41148,398-13.24-62.45%

Decibel Therapeutics Description

Decibel Therapeutics Inc is a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments for hearing and balance disorders. It aims to restore and improve hearing and balance through the restoration and regeneration of functional hair cells and non-sensory support cells within the inner ear. Its lead gene therapy product candidate is DB-OTO which provides hearing to individuals born with profound hearing loss due to an OTOF deficiency. The firm's pipeline products comprise DB-ATO, AAV.103, AAV.104, AAV.201, DB-020, and Cochlear Hair Cell Regeneration.


Your Recent History
NASDAQ
DBTX
Decibel Th..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.